Xilio Therapeutics Inc (XLO)

In the past 90 days, Xilio Therapeutics Inc. has recorded three insider trading transactions, all of which were purchases, totaling approximately $72,765. The notable transactions include two significant buys by insider Shannon James Samuel on June 16 and June 17, amounting to $48,085 combined, and a purchase by President and CEO Russo Rene for about $24,680. The company's stock has declined by 16.3% over the last 90 days, and the last earnings report indicated a significant earnings miss of 63.64%.

Track

Stock chart
Ticker: XLO Exchange: NSM


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Earnings
Earnings
 
Value bought

Past 90 days

 
Value sold

Past 90 days

 
Net insiders buying

Past 90 days

 
Trades (buy and sell)

Past 90 days

Abbreviations B: Buy, S: Sell, PP: Planned purchase, PS: Planned sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2025-06-18 2025-06-17 B Purchase

Shannon James Samuel

Non-Executive Director
1,000 +55.6%
0.69
USD 17,215 		1,000 +55.6% 0.69 USD 100,000
2025-06-18 2025-06-16 B Purchase

Shannon James Samuel

Non-Executive Director
1,000 +inf%
0.69
USD 30,870 		1,000 +inf% 0.69 USD 100,000
2025-06-18 2025-06-16 B Purchase

Russo Rene

PRESIDENT AND CEO

Executive Director
1,000 +14.8%
0.68
USD 24,680 		1,000 +14.8% 0.68 USD 100,000
2025-01-03 2025-01-02 PS Planned sale

Brennan Kevin M.

SVP, FINANCE AND ACCOUNTING

Officer
1,803 -36.1%
0.98
USD 1,774 		1,803 -36.1% 0.98 USD 1,774
2025-01-03 2025-01-02 PS Planned sale

Frankenfield Christopher James

Chief Financial Officer

Officer
6,954 -35.9%
0.98
USD 6,841 		6,954 -35.9% 0.98 USD 6,841
2024-12-19 2024-12-18 B Purchase

GILEAD SCIENCES, INC.

Large shareholder
1,759,978 +24.0%
1.04
USD 1,830,377 		1,759,978 +24.0% 1.04 USD 1,830,377
2024-04-03 2024-04-02 B Purchase

GILEAD SCIENCES, INC.

Large shareholder
485,250 +7.1%
0.76
USD 368,790 		485,250 +7.1% 0.76 USD 368,790
2024-02-09 2024-02-08 S Sale

Atlas Venture Fund XI, L.P.

Large shareholder
267 -0.0%
0.64
USD 171 		267 -0.0% 0.64 USD 171
2024-02-09 2024-02-08 S Sale

Atlas Venture Fund XI, L.P.

Large shareholder
733 -0.0%
0.64
USD 469 		733 -0.0% 0.64 USD 469
2024-01-16 2024-01-12 S Sale

Atlas Venture Fund XI, L.P.

Large shareholder
560 -0.1%
0.83
USD 465 		560 -0.1% 0.83 USD 465
2024-01-16 2024-01-12 S Sale

Atlas Venture Fund XI, L.P.

Large shareholder
1,540 -0.1%
0.83
USD 1,278 		1,540 -0.1% 0.83 USD 1,278
2024-01-16 2024-01-11 S Sale

Atlas Venture Fund XI, L.P.

Large shareholder
569 -0.1%
0.87
USD 495 		569 -0.1% 0.87 USD 495
2024-01-16 2024-01-11 S Sale

Atlas Venture Fund XI, L.P.

Large shareholder
1,566 -0.1%
0.87
USD 1,362 		1,566 -0.1% 0.87 USD 1,362
2021-12-10 2021-12-10 B Purchase

Bain Capital Life Sciences Investors, LLC

Large shareholder
3,188 +0.1%
10.24
USD 32,638 		3,188 +0.1% 10.24 USD 32,638
2021-12-10 2021-12-10 B Purchase

Bain Capital Life Sciences Investors, LLC

Large shareholder
21,812 +0.8%
9.56
USD 208,564 		21,812 +0.8% 9.56 USD 208,564
2021-12-10 2021-12-09 B Purchase

Bain Capital Life Sciences Investors, LLC

Large shareholder
4,011 +0.1%
9.84
USD 39,485 		4,011 +0.1% 9.84 USD 39,485
2021-12-10 2021-12-08 B Purchase

Bain Capital Life Sciences Investors, LLC

Large shareholder
13,458 +0.5%
9.62
USD 129,474 		13,458 +0.5% 9.62 USD 129,474
2021-10-28 2021-10-26 B Purchase

Flynn James E

Large shareholder
387,500 +51.2%
16.00
USD 6,200,000 		387,500 +51.2% 16.00 USD 6,200,000
2021-10-28 2021-10-26 B Purchase

Flynn James E

Large shareholder
387,500 +51.2%
16.00
USD 6,200,000 		387,500 +51.2% 16.00 USD 6,200,000
2021-10-26 2021-10-26 B Purchase

Atlas Venture Fund XI, L.P.

Large shareholder
187,500 +34.2%
16.00
USD 3,000,000 		187,500 +34.2% 16.00 USD 3,000,000
// ... existing code ...